Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 20/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 6/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.85 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.68 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.68 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.67 |
| ▸ | TSPO | P30536 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30195805 | 0.92 | P2RY14 (1.00) | P2RY14OPRD1SIGMAR1KCNH2TMEM97 | |
| SCHEMBL22996148 | 0.92 | P2RY14 (1.00) | P2RY14OPRD1SIGMAR1KCNH2TMEM97 | |
| SCHEMBL30497387 | 0.89 | P2RY14 (0.80) | P2RY14OPRD1SIGMAR1KCNH2ADRA2A | |
| SCHEMBL21248148 | 0.88 | P2RY14 (0.79) | P2RY14OPRD1SIGMAR1KCNH2ADRA2A | |
| SCHEMBL29691860 | 0.85 | P2RY14 (1.00) | P2RY14OPRD1KCNH2TMEM97TSPO | |
| SCHEMBL182551 | 0.84 | P2RY14 (0.78) | P2RY14OPRD1SIGMAR1KCNH2ADRA2A | |
| SCHEMBL29691902 | 0.82 | P2RY14 (1.00) | P2RY14OPRD1KCNH2TMEM97TSPO | |
| SCHEMBL30608312 | 0.82 | P2RY14 (0.89) | P2RY14OPRD1KCNH2TMEM97TSPO | |
| SCHEMBL21263910 | 0.81 | P2RY14 (1.00) | P2RY14OPRD1SIGMAR1ADRA2AADRA2B | |
| SCHEMBL29691872 | 0.80 | P2RY14 (1.00) | P2RY14OPRD1SIGMAR1KCNH2TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584736-B2 | Heterocyclic P2Y14 receptor antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584736-B2 | Heterocyclic P2Y14 receptor antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210047293-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-18 | — | — | US | disclosed |
| US-20210047293-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-18 | — | — | US | disclosed |
| WO-2019157417-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584736-B2 | Heterocyclic P2Y14 receptor antagonists | P2RY14, P2RY1, P2RY13 | P2RY14 1/4885OPRD1 241/4885SIGMAR1 314/4885 |
| US-20210047293-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | P2RY14, P2RY1, P2RY13 | P2RY14 1/4885OPRD1 241/4885SIGMAR1 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.